CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities
Net income	$ 288,576	$ 323,187
Adjustments to reconcile net income to net cash provided by operating activities:
Deferred income tax	29,258	65,600
Depreciation and amortization	12,507	10,376
Amortization of inventory fair value adjustments included in cost of products sold	2,743	0
Stock-based compensation	6,021	1,463
Amortization of debt discount and issuance costs	1,491	6,778
Amortization of deferred royalty obligation value adjustment	482	0
Changes in fair values of equity and long-term investments, net	66,448	(132,485)
Loss on extinguishment of debt	20,662	0
Net gain on sale of TRC	(266,696)	0
Other	995	(251)
Changes in operating assets and liabilities:
Accounts receivable	(867)	0
Receivables from collaboration arrangement	2,385	(7,340)
Inventory	350	0
Prepaid expenses	277	770
Other assets, current	692	328
Other assets, non-current	(3,624)	0
Accounts payable	958	23
Accrued personnel-related expenses and other accrued liabilities	(1,709)	(533)
Accrued interest payable	(1,926)	(2,484)
Income tax payable	33,804	0
Net cash provided by operating activities	192,827	265,432
Cash flows from investing activities
Purchases of equity and long-term investments	(58,725)	(46,373)
Purchases of equity investments managed by ISP Fund LP	(92,951)	(178,445)
Sales of equity investments managed by ISP Fund LP	24,281	21,426
Purchase and sales of other investments managed by ISP Fund LP, net	(41,330)	267,019
Purchases of property and equipment	(33)	0
Proceeds from sale of ownership interest in TRC, net	248,191	0
Cash acquired through the consolidation of Entasis	23,070	0
Cash paid for the acquisition of La Jolla Pharmaceutical Company, net of cash acquired	(150,459)	0
Net cash (used in) provided by investing activities	(47,956)	63,627
Cash flows from financing activities
Distributions to noncontrolling interests	(69,811)	(46,358)
Purchase of Entasis noncontrolling interest	(42,395)	0
Repurchase of common stock	0	(394,149)
Repurchase of shares to satisfy tax withholding	(71)	(47)
Proceeds from issuances of common stock, net	342	123
Payment for repurchase of convertible subordinated notes due 2023	(165,131)	0
Purchases of capped call options associated with convertible senior notes due 2028	(21,037)	0
Proceeds from issuance of convertible senior notes due 2028, net of issuance costs	252,536	0
Net cash used in financing activities	(45,567)	(440,431)
Net increase (decrease) in cash, cash equivalents and restricted cash	99,304	(111,372)
Cash and cash equivalents at beginning of period	201,525	246,487
Cash, cash equivalents and restricted cash at end of period	300,829	135,115
Supplemental Disclosure of Cash Flow Information:
Cash paid for interest	11,736	9,933
Cash paid for income taxes	3,859	0
Reconciliation of Cash, Cash Equivalents and Restricted Cash:
Cash and cash equivalents	300,789	135,115
Restricted cash, included in "Other assets"	40	0
Total cash, cash equivalents and restricted cash at end of period shown in the condensed consolidated statements of cash flows	300,829	135,115
ASU 2020-06
Supplemental Disclosure of Non-cash Investing and Financing Activities:
Adoption of ASU 2020-06	$ 28,123	$ 0